BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 28179355)

  • 1. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
    Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.
    Fiala O; Pesek M; Finek J; Svaton M; Sorejs O; Bortlicek Z; Kucera R; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):461-6. PubMed ID: 26722082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
    Sone K; Oguri T; Ito K; Kitamura Y; Inoue Y; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Asano T; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
    Anticancer Res; 2017 Sep; 37(9):5125-5131. PubMed ID: 28870944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
    Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
    Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
    Svaton M; Blazek J; Krakorova G; Pesek M; Buresova M; Teufelova Z; Vodicka J; Hurdalkova K; Barinova M; Topolcan O
    Anticancer Res; 2021 Apr; 41(4):2053-2058. PubMed ID: 33813413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
    Chen F; Luo X; Zhang J; Lu Y; Luo R
    Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
    Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
    Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
    Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW
    Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer.
    Alm El-Din MA; Farouk G; Nagy H; Abd Elzaher A; Abo El-Magd GH
    Int J Biol Markers; 2012 Jul; 27(2):e139-46. PubMed ID: 22467097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer.
    Baek AR; Seo HJ; Lee JH; Park SW; Jang AS; Paik SH; Koh ES; Shin HK; Kim DJ
    Cancer Biomark; 2018; 22(1):55-62. PubMed ID: 29630519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction chemotherapy for unresectable Stage III non-small-cell lung cancer may improve survival of induction chemotherapy responders as predicted by elevated levels of carcinoembryonic antigen and cytokeratin fragment 19 and classification as stage N3 cancer.
    Li Q; Jiang M; Han X; Yang Z; Shu W; Ding X
    J Cancer Res Ther; 2020; 16(2):222-229. PubMed ID: 32474505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
    Zhao T; Mao G; Chen M
    Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.